Identification of noval diagnostic biomarker for HFpEF based on proteomics and machine learning

Abstract Background Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome that currently lacks effective biomarkers for early diagnosis and treatment. This study seeks to identify new potential biomarkers for HFpEF using proteomics and machine learning. Methods Plasma samples...

Full description

Bibliographic Details
Published in:	Proteome Science
Main Authors:	Muyashaer Abudurexiti, Salamaiti Aimaier, Nuerdun Wupuer, Dongqin Duan, Aihaidan Abudouwayiti, Meiheriayi Nuermaimaiti, Ailiman Mahemuti
Format:	Article
Language:	English
Published:	BMC 2025-04-01
Subjects:	HFpEF SERPINA3 Proteomics Machine learning Biomarker
Online Access:	https://doi.org/10.1186/s12953-025-00242-7

Similar Items

Integrated proteomic and metabolomic profiling reveals novel insights on the inflammation and immune response in HFpEF
by: Muyashaer Abudurexiti, et al.
Published: (2024-07-01)

Untargeted metabolomics unveils metabolic biomarkers in HFpEF
by: Dongqin Duan, et al.
Published: (2025-10-01)

HFpEF Diagnosis: A Challenge in CKD with Current Algorithms
by: Anca E. Stefan, et al.
Published: (2026-06-01)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
by: Norman Mangner, et al.
Published: (2023-10-01)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
by: Leonie Grossekettler, et al.
Published: (2020-05-01)

The Possible Role of Rosuvastatin Therapy in HFpEF Patients—A Preliminary Report
by: Tomasz Urbanowicz, et al.
Published: (2024-11-01)

Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF
by: Lingyun Luo, et al.
Published: (2025-04-01)

The gut microbiota-inflammation-HFpEF axis: deciphering the role of gut microbiota dysregulation in the pathogenesis and management of HFpEF
by: Shenghua Zhou, et al.
Published: (2025-03-01)

Adipose Tissue, Natriuretic Peptides, and HFpEF: Clinical Implications of the Obesity Paradox
by: Michał Maksymilian Wilk, et al.
Published: (2026-06-01)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
by: Paolo Morfino, et al.
Published: (2022-08-01)

Hemodynamic force assessment by cardiovascular magnetic resonance in HFpEF: A case-control substudy from the HFpEF stress trialResearch in context
by: Sören J. Backhaus, et al.
Published: (2022-12-01)

Nitric oxide metabolites: associations with cardiovascular biomarkers and clinical parameters in patients with HFpEF
by: Karsten Piatek, et al.
Published: (2022-12-01)

A New Medical Decision Support System for Diagnosing HFrEF and HFpEF Using ECG and Machine Learning Techniques
by: Pinar Ozen Kavas, et al.
Published: (2022-01-01)

Incidence and causal association of functional atrial mitral regurgitation in HFpEF
by: Nikos T. Kouris, et al.
Published: (2023-01-01)

Sex‐related pathophysiological mechanisms may be present before symptoms of HFpEF develop
by: B. Wong, et al.
Published: (2025-06-01)

Leucine Supplementation Improves Diastolic Function in HFpEF by HDAC4 Inhibition
by: Paula Ketilly Nascimento Alves, et al.
Published: (2023-11-01)

Effects of different exercise programs on the cardiorespiratory reserve in HFpEF patients: a systematic review and meta-analysis
by: Aristi Boulmpou, et al.
Published: (2022-03-01)

The HFA‐PEFF score identifies ‘early‐HFpEF’ phenogroups associated with distinct biomarker profiles
by: Michiel T.H.M. Henkens, et al.
Published: (2022-06-01)

Mitochondrial dysfunction as a therapeutic nexus in HFpEF: therapeutic target and pharmacological advances
by: Tian Yue, et al.
Published: (2025-09-01)

Sex differences in the association between nutritional status and in‐hospital mortality in HFpEF patients
by: Michał Czapla, et al.
Published: (2025-08-01)

Specific targeting of adipose tissue metabolism is superior to caloric restriction in treating obesity-related HFpEF
by: Simon Sedej, et al.
Published: (2025-07-01)

Strengths and limitations of HFpEF probability scores in the era of precision medicine
by: Michał Wilk, et al.
Published: (2026-04-01)

Dynamic aspects of ventricular interaction during exercise in HFpEF and in pre‐capillary pulmonary hypertension
by: Mathias Claeys, et al.
Published: (2023-02-01)

Schaftoside improves HFpEF through regulation the autophagy-lysosome pathway by allosterically targeting CaMKII-δ
by: Haiying Zhang, et al.
Published: (2024-12-01)

Percent Predicted Peak Exercise Oxygen Pulse Provides Insights Into Ventricular-Vascular Response and Prognosticates HFpEF
by: Jason P. Li, MD, et al.
Published: (2024-08-01)

Cardiometabolic Phenotype in HFpEF: Insights from Murine Models
by: Ekaterina Ogurtsova, et al.
Published: (2025-03-01)

Phenotypic Trajectories From Acute to Stable Phase in Heart Failure With Preserved Ejection Fraction: Insights From the PURSUIT‐HFpEF Study
by: Yuki Matsuoka, et al.
Published: (2025-02-01)

Aortic flow is abnormal in HFpEF [version 2; peer review: 2 approved]
by: Pankaj Garg, et al.
Published: (2024-03-01)

Hepatocyte growth factor and B-type natriuretic peptide as independent predictors of mortality in HFpEF patients
by: Hou-liang Chen, et al.
Published: (2025-02-01)

Correction: Strengths and limitations of HFpEF probability scores in the era of precision medicine
by: Michał Wilk, et al.
Published: (2026-06-01)

Leucine Supplementation Prevents the Development of Skeletal Muscle Dysfunction in a Rat Model of HFpEF
by: Paula Ketilly Nascimento Alves, et al.
Published: (2024-03-01)

Gender-Specific Differences in Diastolic Dysfunction and HFpEF: Pathophysiology, Diagnosis, and Therapeutic Strategies
by: Francesca Coppi, et al.
Published: (2025-06-01)

Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF
by: Zhen-Yu Yang, et al.
Published: (2025-08-01)

The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications
by: Xiangling Duan, et al.
Published: (2025-04-01)

Prognosis of early‐stage HFpEF in the community‐dwelling elderly: The Northern Shanghai Study
by: Weilun Meng, et al.
Published: (2025-02-01)

Longitudinal association between N-terminal B-type natriuretic peptide, anxiety and social support in patients with HFpEF: results from the multicentre randomized controlled Aldo-DHF trial
by: Marieke R. Wilke, et al.
Published: (2023-04-01)

Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study
by: Arif Albulushi, et al.
Published: (2025-07-01)

Circulating mediators linking cardiometabolic diseases to HFpEF: a mediation Mendelian randomization analysis
by: Mingzhi Lin, et al.
Published: (2025-05-01)

Unveiling the vulnerability of C57BL/6J female mice to HFpEF and its related complications
by: B. Srinivas, et al.
Published: (2024-03-01)

Arterial Stiffness Is an Important Predictor of Heart Failure with Preserved Ejection Fraction (HFpEF)—The Effects of Phosphate Retention
by: Yuji Mizuno, et al.
Published: (2024-05-01)